(MedPage Today) — In updated results from the LINKER-MM2 trial presented at the recent American Society of Clinical Oncology meeting, the combination of linvoseltamab (Lynozyfic) and carfilzomib (Kyprolis) produced deep, durable responses in patients…
Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116387
Author :
Publish date : 2025-07-07 16:33:00
Copyright for syndicated content belongs to the linked Source.
